

MEDICARE REIMBURSEMENT RATES

	SYNVISC® (hylan G-F 20)	Synvisc-One® (hylan G-F 20)
Number of syringes	3 (16 mg/syringe)	1 (48 mg/syringe)
Medicare allowable* ASP +6.0% (per course of treatment)		
Medicare allowable* ASP +6.0% (per syringe)		
Medicare allowable* ASP +6.0% (per 1 mg)		
Medicare allowable† ASP +4.3% (per course of treatment)		
Medicare allowable† ASP +4.3% (per syringe)		
Medicare allowable† ASP +4.3% (per 1 mg)		
HCPCS code	J7325	J7325

*Reimbursement information obtained from CMS Web site at www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html. Accessed on

†As of March 1, 2013, Medicare is subject to the sequester in the form of provider payment cuts of up to 2%.

This information is provided as an estimate on what a provider may expect as reimbursement.

Providers are responsible for the selection of appropriate codes depending on clinical diagnosis. Providers retain sole responsibility for determining reimbursement and for ensuring the accuracy of their claims submission. Sanofi cannot be responsible for failure of a provider to obtain reimbursement.

SANOBI BIOSURGERY 

Manufactured by
Genzyme, a Sanofi Company
55 Cambridge Parkway
Cambridge, MA 02142
1-888-3-SYNVISC

SYNVISC, Synvisc-One and Genzyme are registered trademarks of Genzyme, a Sanofi Company.

© SANOFI US. All rights reserved. Printed in the USA. US.SYN.